Histogenics (HSGX) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Histogenics (HSGX) Misses Q1 EPS by 1c

Histogenics Corporation Announces First Quarter 2016 Financial and Operating Results

May 12, 2016 6:30 AM EDT

- NeoCart® Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 -

- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT -

WALTHAM, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended March 31, 2016. 

We made significant progress on a number of important business... More